Table II.
Combination of cancer vaccines with PD-1/PD-L1 inhibitors.
| Author(s) (year) | Interventions | Primary end point(s) | Results | (Refs.) |
|---|---|---|---|---|
| Tondini et al, 2019 | DNA vaccine + Anti-PD-1 | Tumor growth | Delayed | (28) |
| Cure rate | 25% | |||
| Xu et al, 2020 | Anti-PD-1 + Lmdd-MPFG vaccine | Percent survival | Prolonged | (29) |
| Tumor volume | Retardation | |||
| TAMS | Converted M2 TAMS to M1 | |||
| PD-L1 | Promoted | |||
| Zhao et al, 2019 | OVA@Mn-DAP vaccine + Anti-PD-1 | Tumor-infiltrating lymphocytes | Increased | (30) |
| Tumor size | Inhibited | |||
| Percent survival | Prolonged | |||
| Gibney et al, 2015 | Nivolumab + A multi-peptide vaccine | CD8+/CD25+Treg/CTLA4+/CD4+ T-cells | Increased | (31) |
| PD-1 | Decreased | |||
| Crosby et al, 2020 | Ad-HER2D16-KI + Anti-PD-1 vs. Anti-PD-1 | Survival | Prolonged | (34) |
| IFN-γ | Increased |
PD-1, programmed cell death protein-1; PD-L1, programmed death protein ligand-1.